Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042109 (urticaria)
 6,569 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The hypereosinophilic syndrome is a multi-organ disease characterized by large counts of eosinophils in peripheral blood observed during at least six months without any evidence for other known causes of eosinophilia. Idiopathic hypereosinophilia is rare and is always diagnosed by exclusion of other disease. This work describes a man aged 21 years who was hospitalized at the Department of Dermatology because of skin manifestations resembling eczema and urticaria. High eosinophil counts in this patient necessitated a wide array of diagnostic tests. The hypereosinophilic syndrome was diagnosed after more than 12 months of follow-up and exclusion of other causes. Corticosteroids and hydroxycarbamide were administered as first-line therapy. Unfortunately, the patient was unresponsive to steroids. Improvement in peripheral eosinophilia after Glivec therapy correlated with improved clinical status.
 ...
PMID:[The hypereosinophilic syndrome: case report]. 1747 38

Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes to avoid unnecessarily discontinuing a potentially lifesaving medication. Adverse cutaneous manifestations in response to imat-inib are not infrequent and can include dry skin, alopecia, facial edema, and photosensitivity rash. Other less common manifestations include exfoliative dermatitis, nail disorders, psoriasis, folliculitis, hypotrichosis, urticaria, petechiae, Stevens-Johnson syndrome, erythema multiforme, Sweet syndrome, and leukocytoclastic vasculitis. We report a case of imatinib-induced lichenoid drug eruption (LDE), a rare cutaneous manifestation, along with a review of the literature.
 ...
PMID:Imatinib mesylate-induced lichenoid drug eruption. 2839 13